Von Willebrand Disease Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Von Willebrand Disease (vWD) Clinical Trials Market Report Overview
In total there were 97 clinical trials conducted on von willebrand disease (vwd), as of June 2023. The von willebrand disease (vWD) clinical trial market research report provides an overview of the Von Willebrand Disease (vWD) Clinical trials scenario. This report provides top-line data relating to the clinical trials on Von Willebrand Disease (vWD) and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
Key Regions | · North America
· Asia-Pacific · Europe · Middle East & Africa · South & Central America |
Key Countries | · The US
· Germany · Austria · The UK · Poland · France · Russia · Italy · Netherlands · Spain |
Key Sponsor Types | · Institution
· Company |
Leading Sponsors | · Octapharma AG
· CSL Ltd · Takeda Pharmaceutical Co Ltd · LFB SA · Bio Products Laboratories Holdings Ltd · Grifols SA · Pfizer Inc · Archemix Corp (Inactive) · Baxter International Inc · F. Hoffmann-La Roche Ltd |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Von Willebrand Disease Clinical Trials Market Segmentation by Regions and Countries
The key regions in the Von Willebrand Disease clinical trials market are North America, Asia-Pacific, Europe, the Middle East & Africa, and South & Central America, among others. Europe dominates the market as of June 2023.
In a country-wise analysis, as of June 2023, the US has the highest number of Von Willebrand Disease (vWD) clinical trials, followed by Germany, Austria, the UK, Poland, France, Russia, Italy, Netherlands, and Spain.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, Germany has the highest proportion of Von Willebrand Disease (vWD) to Hematological Disorders clinical trials as of June 2023. Moreover, most of the clinical trials were conducted in the US.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Russia has the highest proportion of Von Willebrand Disease (vWD) to Hematological Disorders clinical trials as of June 2023. Out of all the clinical trials conducted in the E7 countries, the majority were in Russia.
Von Willebrand Disease Clinical Trials Analysis by Regions, 2023 (%)
Buy the Full Report for More Regional Insights into the Von Willebrand Disease Clinical Trials Market, or Download a Free Report Sample
Von Willebrand Disease Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the Von Willebrand Disease clinical trials market are institution and company. As of June 2023, 65% of trials have been sponsored by Company sponsor type.
Von Willebrand Disease Clinical Trials Market Analysis by Sponsor Types, 2023 (%)
Buy the Full Report for More Sponsor Type Insights into the Von Willebrand Disease Clinical Trials market, or Download a Free Report Sample
Von Willebrand Disease Clinical Trials Market - Competitive Landscape
The leading sponsors in the Von Willebrand Disease clinical trials market are Octapharma AG, CSL Ltd, Takeda Pharmaceutical Co Ltd, LFB SA, Bio Products Laboratories Holdings Ltd, Grifols SA, Pfizer Inc, Archemix Corp (Inactive), Baxter International Inc, and F. Hoffmann-La Roche Ltd. Octapharma AG led the Von Willebrand Disease clinical trials market in June 2023.
Von Willebrand Disease Clinical Trials Market Analysis by Sponsors, 2023 (%)
Buy the Full Report for More Insights into the Leading Sponsors in the Von Willebrand Disease Clinical Trials Market, Or Download a Free Report Sample
Segments Covered in the Report
Von Willebrand Disease Clinical Trials Regional Outlook (2023)
- North America
- Asia-Pacific
- Europe
- Middle East & Africa
- South & Central America
Von Willebrand Disease Clinical Trials Country Outlook (2023)
- The US
- Germany
- Austria
- The UK
- Poland
- France
- Russia
- Italy
- Netherlands
- Spain
Von Willebrand Disease Clinical Trials Sponsor Type Outlook (2023)
- Institution
- Company
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type, and End point status
- The report reviews the top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended, and Withdrawn) with a reason for unaccomplishment
- The report provides enrollment trends for the past five years
- Report provides the latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regard to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country level
CSL Ltd
Takeda Pharmaceutical Co Ltd
LFB SA
Bio Products Laboratories Holdings Ltd
Grifols SA
Pfizer Inc
Archemix Corp (Inactive)
Baxter International Inc
F. Hoffmann-La Roche Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
Which is the leading region in the Von Willebrand Disease clinical trials market?
Europe is the leading region in the Von Willebrand Disease clinical trials market as of June 2023.
-
Which is the leading country in the Von Willebrand Disease clinical trials market?
The US is the leading country in the Von Willebrand Disease clinical trials market as of June 2023.
-
Which is the leading sponsor type in the Von Willebrand Disease clinical trials market?
Company is the leading sponsor type in the Von Willebrand Disease clinical trials market as of June 2023.
-
Who are the leading sponsors in the Von Willebrand Disease clinical trials market?
The leading sponsors in the Von Willebrand Disease clinical trials market are Octapharma AG, CSL Ltd, Takeda Pharmaceutical Co Ltd, LFB SA, Bio Products Laboratories Holdings Ltd, Grifols SA, Pfizer Inc, Archemix Corp (Inactive), Baxter International Inc, and F. Hoffmann-La Roche Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.